에 대한 최신 뉴스 Geovax Labs (NASDAQ:GOVX) 주식

Geovax Labs

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Broad U.S. Equity ETFs

Exclusives

Tech

Trading Ideas

ETFs

AAPL

AMZN

APDN

ASTS

CING

CRWD

GOVX

INDO

LUMN

LUNR

NVDA

PLTR

SERV

SMCI

TSLA

VRAX

ZAPP

매일의 거래일에는 트레이더들이 전체 시장과 개별 종목들에 대한 최신 뉴스를 볼 수 있는 소스인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 2024년 8월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보자. 현재 가격과 연간 실적은 8월 30일을 기준으로 하며 배당금은 포함되지 않았다. 4월 검색결과는 추적되지 않았다.

단독: 2024년 8월 벤징가 프로에서 가장 검색량이 많았던 상위 20개 티커는?

Biotech

News

Health Care

After-Hours Center

Movers

지오백스 랩스(NASDAQ:GOVX)의 주가는 수요일 뉴욕 시장 마감을 앞두고 급등했고, 미시간주 웨인(Wayne) 카운티에서 2022년 이후 첫 번째 엠폭스(mpox, 원숭이두창) 사례가 확인됐다는 보도가 나온 후 시간외 거래에서 계속해서 반등했다.

지오백스의 주식, 수요일 시장 마감 직전부터 시간외 거래까지 급등 지속: 무슨 일이?

Geovax Labs Inc

<a href="https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.">https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.</a>
&nbsp;
EMA has recommended extending the indication of the smallpox and mpox vaccine <a href="https://www.ema.europa.eu/node/65501">Imvanex</a> to adolescents from 12 to 17 years of age.
Imvanex is already authorised in the European Union (EU) to protect against smallpox, mpox and the disease caused by the vaccinia virus in adults. It contains a live, highly weakened form of a virus called "modified vaccinia virus Ankara" (MVA-BN), which is related to the smallpox virus. EMA's human medicines committee (CHMP) based the recommendation to extend the use of Imvanex to adolescents on the <a href="https://www.clinicaltrials.gov/study/NCT05740982">interim results of a study</a> that compared the vaccine's ability to generate an immune response (produce virus-specific antibodies) in 315 adolescents and in 211 adults.
The immune response in adolescents was similar to adults. Therefore, it is inferred that the vaccine will provide similar protection in adolescents to that expected in adults. According to the submitted data, the safety profile of Imvanex in adolescents was comparable to that seen in adults and no additional risk has been identified. As part of its recommendation, EMA has requested the marketing authorisation holder to submit the final results of the study by 30 May 2025 to further characterise the information about safety in adolescents.
The Agency's assessment has important implications for the global response to the mpox outbreak in the Democratic Republic of the Congo (DRC) and other countries, which was <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">declared a public health emergency of international concern (PHEIC)</a> by the World Health Organization (WHO) on 14 August 2024.
EMA is the regulatory agency of record for <a href="https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox">prequalification of this vaccine by WHO</a> on 13 September 2024. This means that CHMP's assessment constitutes the basis for WHO prequalification approval to facilitate timely and increased access to this vaccine in communities with urgent need. Previously, EMA's assessment was also taken into account by the national regulatory authority of the DRC in the fast-track approval of the vaccine. In addition, WHO has cooperated in EMA's assessment of the extension of indication in adolescents, a population that is particularly vulnerable to mpox.
Mpox is a disease that is transmitted to people by animals, mainly rodents, but can also spread between people with direct contact. It is endemic in certain parts of Central and West Africa. The current surge in cases in the DRC and several neighbouring countries is driven by the mpox clade I strain that is known to cause a more severe form of mpox in humans than the mpox clade II strain that spread during the 2022/2023 PHEIC. Mpox can be fatal for people with weak immune systems.
Data indicate that Imvanex protects against both the clade I and clade II mpox strains.
In the EU, decisions on how vaccinations should be given are the prerogative of the expert bodies guiding vaccination campaigns in each Member State. The European Centre for Disease Prevention and Control (ECDC) <a href="https://www.ecdc.europa.eu/en/infectious-disease-topics/mpox/rapid-scientific-advice-public-health-measures-mpox-2024">published advice for public health authorities for mpox</a> on their website.

Global

General

AEMD

CMRX

MRNA

TNXP

'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA

US To Stay Committed In Bringing Mpox Outbreak Under Control

Morocco Records First Case Of Mpox

Macro Economic Events

Economics

CDC Says There Have Been No Reported Cases Of Clade I Mpox In The U.S. As Of September 6; In The U.S., Clade II Mpox Is Still Circulating At Low Levels

<a href="https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926">https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926</a>
&nbsp;
Senior Biden administration officials said Friday that the United States is preparing for the possible arrival of <a href="https://www.nbcnews.com/health/health-news/mpox-strain-spreads-cdc-who-stronger-warnings-rcna165155">a more severe version of mpox</a>, which has taken off in the Democratic Republic of Congo and other countries in Africa resulting in more than 600 deaths there.
As of Thursday, there have been more than 24,800 reported cases of this version of the virus, <a href="https://www.nbcnews.com/health/health-news/mpox-virus-outbreak-symptoms-2024-spread-rcna166778">known as clade 1</a>, so far this year, the World Health Organization said at a separate briefing Friday.&nbsp;The WHO declared the outbreak a<a href="https://www.nbcnews.com/health/health-news/who-declares-mpox-global-public-health-emergency-second-time-rcna166601"> global health emergency</a> in August.
Last month,<a href="https://www.nbcnews.com/health/health-news/sweden-confirms-first-case-mpox-strain-congo-rcna166763"> Sweden confirmed a case of clade 1</a>, the first known case outside of Africa, followed by a case in Thailand several days later. Both patients had spent time in Africa.
A different version of mpox, clade 2, triggered a global outbreak in 2022 and a surge of cases in the U.S. Clade 1 is more severe and can kill up to 10% of people infected, though recent death rates have been around 1% to 3.3%, <a href="https://www.cdc.gov/poxvirus/mpox/about/index.html">according to the CDC.</a>
On a call with reporters, senior administration officials said that as infections have risen in Africa, the U.S. has been gearing up for its own cases.&nbsp;
"We've been preparing for the arrival of clade 1 in the United States for many months now, especially as we saw the outbreak in DRC and neighboring countries accelerate," one official said.
The government is expanding its mpox surveillance efforts, primarily through wastewater analysis, and is reaching out to the medical community to educate members on what to watch for, including the severity of clade 1 and how it spreads, according to officials.
Officials said they're also making sure testing is more widely available.
Any doctor in the U.S. can order an mpox test that can be run through a national laboratory. If positive, it can be tested for clade 2. If those results are negative for clade 2, the doctor can make a presumptive diagnosis of clade 1; that diagnosis will need to be officially confirmed by the Centers for Disease Control and Prevention, according to officials.
The Jynneos mpox vaccine, given in two doses, is effective against both clade 1 and clade 2 of mpox.
The CDC's vaccine recommendation remains limited to anyone who is considered at high risk of catching the virus, mainly gay and bisexual men.&nbsp;
Most people with health insurance can get the vaccine at major pharmacy retail chains including CVS and Walgreens, the officials said. The vaccine is also available for free at public health departments and community health centers.
More vaccines are being held in the U.S. national stockpile, officials said, although they declined to say how many.&nbsp;
"There is a sufficient amount of vaccine for the U.S. population," an official said.&nbsp;
The U.S. is also working with government scientists and drug companies to develop potential new treatments. There are currently no approved treatments for mpox. The Food and Drug Administration has approved an antiviral treatment known as TPOXX for smallpox, which is closely related to mpox, although a recent clinical trial found that the drug is <a href="https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo">not effective against clade 1</a>.&nbsp;

'U.S. Prepares For Possible Arrival Of More Severe Strain Of Mpox; There Have Been Nearly 25,000 Cases Of The Clade 1 Version Of Mpox In Africa So Far This Year" - NBC

<a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523">https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523</a>
&nbsp;
Today, close to 100,000 mpox vaccine doses will arrive in the Democratic Republic of Congo (DRC), making these the first delivery of the vaccine to the country. A second delivery amounting to around 100,000 vaccines is expected to arrive in the coming days.
These vaccines are part of the 215,000 MVA-BN&#xAE; <a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4244">vaccine doses</a> that the European Commission's Health Emergency Preparedness and Response Authority (HERA) procured and pledged to share to affected countries in Africa as an immediate response to the mpox outbreak.
Via Team Europe, an additional 351,500 of doses from France, Germany, Spain, Malta, Portugal, Luxembourg, Croatia, Austria, Poland, and potentially some other Member States, will be donated to the Africa CDC to distribute to affected countries. This brings the total number of vaccine doses donated from Team Europe to at least 566,500, which includes the above 215,000 doses that were donated by HERA in cooperation with the Bavarian Nordic pharmaceutical company.
EU support for the mpox outbreak
This initiative is part of a comprehensive set of EU actions put in place as part of the EU Global Health Strategy, which represents the external dimension of a strong European Health Union and is a key component of Global Gateway, to support partners in the rest of the world.
The Commission is actively coordinating the response of EU Member States to the mpox outbreak via regular meetings of the HERA Board and the Health Security Committee, which allows prompt coordination when dealing with health threats.
The Emergency Response Coordination Centre (ERCC) is in contact with EU Member States given that, if activated, the EU Civil Protection Mechanism (rescEU) can be used to channel mpox vaccines and therapeutics to countries in need. Specialised expertise, medical items and equipment could also be deployed based on these needs.
Under the Global Gateway investment strategy, the Commission is committed to advancing public health in Africa. The Commission has focused on strengthening health systems, securing pharmaceutical supply chains, and developing local manufacturing through investment in infrastructure and a supportive regulatory environment. An example of this is the Team Europe Initiative on manufacturing and access to vaccines, medicines and health technologies (Mav+) and on Sustainable Health Security.
The European Centre for Disease Prevention and Control (ECDC) is supporting epidemiological work on the ground in the DRC, working with the Africa CDC to identify priority areas for mpox research, and is leading coordination of the Network of Major CDCs globally. HERA is also working with the Africa CDC with the aim of expanding access to mpox diagnostics and sequencing in the region, with a €9.4 million grant foreseen for early autumn.
The Commission has released €1 million in humanitarian aid to support care, prevention, epidemiological surveillance, risk communication and distribution of kits in the eastern DRC as well as €200,000 in Burundi to assist the Burundi Red Cross in preparing for and responding to the epidemic. Under the European Humanitarian Response Capacity (EHRC), in cooperation with the ECDC, two epidemiologists were deployed on 4 September to the DRC. In addition, the Commission provides regular humanitarian funding for surveillance programmes, including in Uganda and Kenya's camps and settlements and expertise to assist in the response.

'First Delivery Of Mpox Vaccine Doses From The Commission Arrive Today In The Democratic Republic Of Congo' - European Commission

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent080124&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">and individual tickers.</a>
Here is a look at the most-searched stocks on Benzinga Pro for the month of August 2024. Current prices and year-to-date performance are based on Aug. 30 and do not include dividends. April search results were not tracked.
1. NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>Current Price: $119.37</li>
<li>52-Week Range: $39.23 to $140.76</li>
<li>Year-to-Date Return: +147.8%</li>
<li><a href="https://www.benzinga.com/news/earnings/23/02/30713474/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-january-where-do-spy-tesla-apple-and-ford">January</a>/<a href="https://www.benzinga.com/markets/penny-stocks/23/03/31137326/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-february-including-tesla-apple-and">February</a>/<a href="https://www.benzinga.com/markets/equities/24/04/38023764/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-march-where-do-tesla-nvidia-spy-and-re">March </a>Search Ranking: 3rd/1st/1st</li>
<li><a href="https://www.benzinga.com/exclusives/24/06/39234936/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-may-where-do-nvidia-tesla-gamestop-amc-ran">May</a>/<a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple">June</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow">July </a>Search Ranking: 2nd/1st/2nd</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>Current Price: $563.68</li>
<li>52-Week Range: $409.22 to $565.22</li>
<li>Year-to-Date Return: +19.3%</li>
<li>January/February/March Search Ranking: 2nd/2nd/3rd</li>
<li>May/June/July Search Ranking: 1st/3rd/3rd</li>
</ul>
3. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>Current Price: $214.11</li>
<li>52-Week Range: $138.80 to $278.97</li>
<li>Year-to-Date Return: -13.8%</li>
<li>January/February/March Search Ranking: 1st/4th/2nd</li>
<li>May/June/July Search Ranking: 4th/4th/1st</li>
</ul>
4. Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>Current Price: $437.70</li>
<li>52-Week Range: $226.59 to $1,229.00</li>
<li>Year-to-Date Return: +53.3%</li>
<li>January/February/March Search Ranking: Not in Top 20/Not in Top 20/5th</li>
<li>May/June/July Search Ranking: 14th/10th/19th</li>
</ul>
5. Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>)
<ul>
<li>Current Price: $5.25</li>
<li>52-Week Range: $0.78 to $7.83</li>
<li>Year-to-Date Return: +17.8%</li>
<li>January/February/March Search Ranking: Not in Top 20</li>
<li>May/June/July Search Ranking: Not in Top 20</li>
</ul>
6. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>Current Price: $229.00</li>
<li>52-Week Range: $164.08 to $237.23</li>
<li>Year-to-Date Return: +23.4%</li>
<li>January/February/March Search Ranking: 5th/8th/4th</li>
<li>May/June/July Search Ranking: 6th/5th/7th</li>
</ul>
7. Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
<ul>
<li>Current Price: $31.48</li>
<li>52-Week Range: $13.68 to $33.12</li>
<li>Year-to-Date Return: +89.9%</li>
<li>January/February/March Search Ranking: Not in Top 20/Not in Top 20/11th</li>
<li>May/June/July Search Ranking: 6th/5th/7th</li>
</ul>
8. Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
<ul>
<li>Current Price: $148.56</li>
<li>52-Week Range: $93.12 to $227.30</li>
<li>Year-to-Date Return: +7.2%</li>
<li>January/February/March Search Ranking: 12th/14th/8th</li>
<li>May/June/July Search Ranking: 8th/9th/4th</li>
</ul>
9. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>Current Price: $476.27</li>
<li>52-Week Range: $342.35 to $503.52</li>
<li>Year-to-Date Return: +18.3%</li>
<li>January/February/March Search Ranking: 18th/Not in Top 20/9th</li>
<li>May/June/July Search Ranking: 9th/11th/11th</li>
</ul>
10. GeoVax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>)
<ul>
<li>Current Price: $4.63</li>
<li>52-Week Range: $1.09 to $11.18</li>
<li>Year-to-Date Return: -16.6%</li>
<li>January/February/March Search Ranking: Not in Top 20</li>
<li>May/June/July Search Ranking: Not in Top 20</li>
</ul>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent090324">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;in the first half of 2024:
11. Indonesia Energy Corporation (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INDO#AMEX">INDO</a>)
12. Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>)
13. Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
14. Cingulate Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>)
15. Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
16. Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>)
17. Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>)
18. AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)
19. CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)
20. Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
Why It's Important: Nvidia was the top searched stock on Benzinga Pro for the month of August thanks to<a href="https://www.benzinga.com/news/earnings/24/08/40613050/nvidia-q2-earnings-guidance-top-street-view-as-ai-fuels-record-data-center-revenue-gross-margin-fal"> its quarterly earnings </a>falling during the calendar month. The company beat estimates from analysts and shared guidance that was ahead of estimates. The stock has consistently ranked as one of the top three most-searched tickers on Benzinga Pro in each month this year. 
Tesla, which topped the month of July, fell to third place for the month of August. The electric vehicle stock has ranked among the four most-searched tickers each month during 2024.
Two ETFs were among the most-searched tickers in August, with SPY ranking second and QQQ ranking ninth. The SPY, which tracks the S&amp;P 500, regularly ranks as one of the top three most searched tickers each month. The QQQ, which tracks the Nasdaq 100, saw a boost in August, re-joining the top 10 for the first time since May.
Super Micro Computer saw a surge in interest in August, likely boosted<a href="https://www.benzinga.com/trading-ideas/short-ideas/24/08/40579899/super-micro-computer-stock-falls-on-short-report-hindenburg-says-company-has-accounting"> by a short report </a>and an update from the company. The stock previously ranked as high as fifth in March before the fourth-place ranking in August. The stock moved back into the top 10 for the first time since June's 10th place ranking.
Two newcomers joined the top 10 most searched tickers list, with Lumen Technologies ranking fifth and GeoVax Labs ranking 10th. Lumen <a href="https://www.benzinga.com/news/24/08/40221474/lumen-technologies-stock-continues-to-soar-whats-going-on">reported quarterly financial results</a> during the month and saw shares soar and gain interest from investors. GeoVax Labs saw high volatility and increased interest related to the<a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal"> emergency health declaration </a>by the World Health Organization on mpox. GeoVax Labs has vaccines that are said to be effective against mpox.
Falling out of the top 10 were Serve Robotics, which ranked 16th in August and Zapp Electric Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>), which did not rank in the top 20 for August.
The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) continues to see strong interest from readers. The ETF, which tracks small cap stocks, ranked 24th in August following a 22nd ranking in July. With a potential Federal Reserve rate cut on the horizon, small cap stocks and ETFs could see increased interest in September.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo created using artificial intelligence via MidJourney.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?

Macro Notification

BWVI

iShares MSCI Israel Capped Investable Market Index Fund

WHO Chief Tedros Says Mpox Vaccines Could Be Ready For Emergency Use Listing Within Two Weeks; Some Mpox Vaccines Expected To Arrive In Congo In The Next Few Days

WHO Chief Tedros Says Received First Expression Of Interest For Emergency Use Listing From Mpox Diagnostics Manufacturer; WHO Officials Discuss Polio Vaccination Plan In Gaza, Confirm Applications From Bavarian Nordic And KM Biologics For Mpox Vaccines Emergency Use Listing, And Announce 230,000 Doses Available For Congo

CDC Says Clade I Mpox Outbreak Originating In Central Africa; Risk Of Mpox Coming Into U.S. Is Low; No Cases Of Clade I Mpox Have Been Reported In The U.S. At This Time; Best Protection Against Mpox Is Two Doses Of Jynneos Vaccine If Eligible; Working With Other U.S. Government Agencies & Partners On Strategy For Vaccination In Democratic Republic Of Congo

Reported Earlier, GeoVax To Raise $5M Through Sale Of 975,610 Shares At $5.125 Each In At-the-Market Offering

<a href="https://www.reviewjournal.com/life/health/mpox-case-reported-at-clark-county-detention-center-3148320/">https://www.reviewjournal.com/life/health/mpox-case-reported-at-clark-county-detention-center-3148320/</a>
&nbsp;
One case of mpox has been reported at the Clark County Detention Center, according to the Metropolitan Police Department.
While police were unable to confirm which date the case was reported, Metro said it was during the week of August 19.
The person with mpox, which is formerly known as monkeypox, is no longer in custody, police said Tuesday, adding that there were no other reported cases.
&nbsp;
According to the Centers for Disease Control, the virus is part of the same family as the virus that causes smallpox. Symptoms commonly include a rash that scabs before healing.
The disease can be spread between animals and people, the <a href="https://www.cdc.gov/poxvirus/mpox/about/index.html">CDC</a> website reads. It is spread through skin-to-skin contact.

Reported August 27, 2024 'Mpox Case Reported At Clark County Detention Center' - Las Vegas Review-Journal

The World Health Organization announced a new strategic preparedness and response plan Monday in the fight against mpox, two weeks after declaring a public health emergency<a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal"> on the outbreak.</a>
What Happened: The WHO announced a new plan in its fight against the outbreak of mpox. The plan comes as several companies are<a href="https://www.benzinga.com/news/24/08/40439999/geovax-labs-stock-continues-to-surge-whats-going-on"> ramping up efforts</a> to launch or increase output of mpox vaccines and treatment options.
The <a href="https://www.who.int/news/item/26-08-2024-global-strategic-preparedness-and-response-plan-launched-by-who-to-contain-mpox-outbreak">plan </a>calls for $135 million in funding for the WHO response and for member states and partners. Among the partners are communities, researchers and the Africa Centres for Disease Control and Prevention.
Funding will help with surveillance, prevention, readiness and the response to fight outbreaks of mpox, the WHO said.
The WHO said it will take part in strategic vaccination efforts to focus on high-risk individuals, which includes health care workers and those with close contact to recent cases.
"The mpox outbreaks in the Democratic Republic of the Congo and neighboring countries can be controlled, and can be stopped," WHO Director-General Dr. Tedros Adhanom Ghebreyesus said. 
"Doing so requires a comprehensive and coordinated plan of action between international agencies and national and local partners, civil society, researchers and manufacturers, and our Member States."
A virtual scientific conference will be held on Aug. 29 and Aug 30 to share mpox research and outbreak control goals from the WHO, Africa CDC and the National Institute of Allergy and Infectious Diseases.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/08/40559658/diagnostic-giants-labcorp-roche-to-ramp-up-testing-capacity-amid-global-concerns-over-new-mpox-str">Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain</a>
Why It's Important: The six-month plan is viewed as the critical step in stopping mpox outbreaks from spreading further or faster.
On Monday, Germany announced it will donate 100,000 mpox vaccine doses from its stockpile to help with the outbreak prevention, as reported by Reuters. Germany will keep a minimum stock of mpox vaccines, the report said. 
There have been 3,326 confirmed cases of mpox in Africa in 2024, with 590 deaths across 12 countries, according to the Africa Centres for Disease Control and Prevention, as <a href="https://thehill.com/policy/healthcare/4847877-who-releases-mpox-outbreak-plan/">reported </a>by The Hill. A total of 17,979 suspected mpox cases have been reported. 
Shares of companies that have mpox vaccines or treatments have been highly volatile over the last two weeks. The list includes Bavarian Nordic (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNRY#OTC">BVNRY</a>) and Emergent Biosolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), both of which have WHO-recommended vaccines
GeoVax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) and SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) have also been highly volatile. GeoVax has a mpox vaccine in clinical development. SIGA Technologies has Tpoxx, which is a treatment for mpox.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40554882/tonix-pharma-collaborates-with-worlds-largest-vaccine-manufacturer-for-mpox-vaccine">Tonix Pharma Collaborates With World&#8217;s Largest Vaccine Manufacturer For Mpox Vaccine</a></li>
</ul>
Illustration via Shutterstock.

BVNRY

SIGA

WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped'

WHO Launches Global Strategic Preparedness And Response Plan To Contain Mpox Outbreak

<a href="https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-member-states-information-session-on-mpox-23-august-2024">https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-member-states-information-session-on-mpox-23-august-2024</a>
Honourable Ministers, Excellencies, dear colleagues and friends,
Good morning, good afternoon and good evening to all Member States, and thank you for joining us once again.
Since the start of the global mpox outbreak in 2022, more than one hundred thousand confirmed mpox cases have been reported to WHO.
The virus continues to circulate at low levels globally.
The African Region has had an unprecedented increase and geographical expansion.
Transmission is now centred in the Democratic Republic of the Congo, with 90% of the reported cases in 2024. There have been more than sixteen thousand suspected cases - including 575 deaths - this year alone.
This upsurge is being driven by two separate outbreaks – in different parts of the country - of two strains, or clades, of the virus that causes mpox.
The rapid spread of a new clade, clade 1b, is the main reason for my decision to declare a public health emergency of international concern, following the International Health Regulations Emergency Committee meeting on the 14th of August 2024.
I issued temporary recommendations five days later.
In the past month, cases of clade 1b have been reported in four countries neighbouring DRC, which had not reported mpox before: Burundi, Kenya, Rwanda and Uganda.
This week, cases have also been reported in Thailand and Sweden.
WHO and partners have developed a Global Mpox Strategic Preparedness and Response Plan to stop outbreaks of human-to-human transmission of mpox through coordinated global, regional, and national efforts.
The plan focuses on implementing comprehensive surveillance and response strategies; advancing research and equitable access to medical countermeasures; minimizing zoonotic transmission; and empowering communities to actively participate in outbreak prevention and control.
At the global-level, the emphasis is on strategic leadership, timely evidence-based guidance, and access to medical countermeasures for the most at-risk groups in affected countries.
We are working with a broad range of international, regional, national and local partners and networks to enhance coordination across key areas of preparedness, readiness and response.
This includes engagement with the Act-A Principals group; the Standing Committee on Health Emergency Prevention, Preparedness and Response; the R&amp;D Blueprint for Epidemics; and the i-MCM Net.
WHO regional offices have also established Incident Management Support Teams – IMSTs- to lead preparedness and response activities, and we are significantly scaling up staff in affected countries.
Within the Africa Region, where need is greatest, the WHO Regional Office for Africa, in collaboration with Africa CDC, will jointly spearhead the coordination of mpox response efforts.
Together, WHO AFRO and Africa CDC have agreed on a one-plan, one-budget approach as part of the Africa Continental Mpox Strategic Preparedness and Response Plan.
At the national and sub-national level, health authorities will adapt strategies to current epidemiological trends.
Let me be clear: this new mpox outbreak can be controlled and can be stopped.
Doing so requires concerted action between international agencies and national and local partners, civil society, researchers and manufacturers, and you, our Member States.
As with all global health actions, our approach must adhere to the principles of equity, global solidarity, community empowerment, human rights, and coordination across sectors.
For today's presentation, on behalf of the mpox IMST, Dr Maria Van Kerkhove and Scott Pendergast will present an overview of the temporary recommendations; actions being taken by WHO, Member States and partners; and an overview of the Global Mpox Strategic Preparedness and Response Plan.
Responding to this complex outbreak requires a comprehensive and coordinated international response.
To fund this work and to stop the outbreak as quickly as possible, our initial estimates are that the SPRP requires approximately US$ 135 million over the next six months for the acute phase of the outbreak.
That amount will likely increase as we update the plan in light of growing needs.
A dedicated WHO funding appeal will be released early next week. We are appealing to donors to provide the needed resources, and thank those who have already made pledges to WHO and other partners.
So far, for this mpox outbreak in 2024, we have released about US$ 1.5 million from the WHO Contingency Fund for Emergencies, and we plan to release more in the coming days, until funding from donors for the response comes in.
WHO will coordinate the global response, working closely with each of the affected countries, to prevent transmission, treat those infected, and save lives.
I'd like to close by noting that today's information meeting was requested by members of the Standing Committee on Health Emergency Prevention, Preparedness and Response, which held their first extraordinary meeting last Thursday, just 24 hours after the PHEIC had been declared.
Further updates will be discussed at the fifth meeting of the Standing Committee on the 3rd and 4th of September.
As always, we are grateful for your engagement with today's presentations, and we look forward to your questions, comments and guidance.
I thank you.&nbsp;

WHO Director-General's Opening Remarks At Member States Information Session On Mpox – 23 August 2024

WHO: Côte d'Ivoire Reports First Cases Of Clade II Mpox Since The Start Of The Multi-Country Outbreak In 2022

U.S. stocks showed signs of resilience as traders eagerly awaited Federal Reserve Chair Jerome Powell&#8217;s address at Jackson Hole on Friday. The minutes from the July FOMC meeting revealed that policymakers were <a href="https://www.benzinga.com/top-stories/24/08/40492530/fed-minutes-reveal-plausible-case-for-interest-rate-cut-as-policymakers-cheer-inflation-progress">considering a potential interest rate cut</a> in September due to progress in curbing inflation, though they agreed to maintain the current rate in July
On Wednesday, major U.S. indices were positive, with the Dow Jones Industrial Average rising 0.1% to 40,890.49, the S&amp;P 500 gaining 0.4% to 5,620.85, and the Nasdaq climbing 0.6% to 17,918.99.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) closed the day with a 2.38% increase at $135.06. The stock hit an intraday high of $135.72 and a low of $130.66. Snowflake&#8217;s 52-week range is $107.93 to $237.72. The data cloud company reported <a href="https://www.benzinga.com/news/earnings/24/08/40494892/snowflake-q2-earnings-revenue-beat-eps-beat-raised-guidance-additional-2-5b-buyback-great-traction-">better-than-expected second-quarter earnings</a> and announced an additional $2.5B buyback.
GeoVax Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) surged by a massive 47.01% to close at $8.35. The stock&#8217;s intraday high was $8.35, and the low was $5.41. GeoVax&#8217;s 52-week range is $1.09 to $11.18. The company&#8217;s shares popped following a report of the <a href="https://www.benzinga.com/general/biotech/24/08/40495643/geovax-labs-stock-surges-ahead-of-the-close-shares-remain-volatile-whats-happening">first case of Mpox</a> in Michigan&#8217;s Wayne County since 2022.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40453509/shiba-inu-lead-developer-shytoshi-kusama-opens-up-on-revealing-true-identity-heres-what-wa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shiba Inu Lead Developer Shytoshi Kusama Opens Up On Revealing True Identity — Here&#8217;s What Was Said</a>
Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) ended the day 1.86% higher at $60.23. The stock&#8217;s intraday high and low were $60.26 and $59.35, respectively. Zoom&#8217;s 52-week range is $55.06 to $75.91. The company posted <a href="https://www.benzinga.com/news/earnings/24/08/40495102/zoom-video-reports-better-than-expected-q2-results-strong-forward-guidance-details">strong second-quarter results</a> and provided robust forward guidance.
Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) saw an impressive 11.20% rise to close at $159.25. The stock&#8217;s intraday high was $167.4, and the low was $158.97. Target&#8217;s 52-week range is $102.93 to $181.86. The retail giant reported <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40492278/targets-strong-q2-performance-impresses-analysts-but-caution-remains-over-future-ma">strong second-quarter performance</a> and raised its outlook, impressing analysts.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) closed the day with a 0.98% gain at $223.27. The stock&#8217;s intraday high was $224.66, and the low was $218.86. Tesla&#8217;s 52-week range is $138.8 to $278.97. The European Union has decided to <a href="https://www.benzinga.com/news/24/08/40479832/elon-musks-tesla-gets-a-breather-as-eu-slashes-tariffs-on-its-china-made-evs-even-as-saic-geely-and">slash tariffs</a> on Tesla&#8217;s China-made electric cars, potentially reshaping the electric car market in the region.
Prepare for the day&#8217;s trading <a href="Premarket Movers &amp; News">with top premarket movers and news</a> by Benzinga.
Photo by WHYFRAME on Shutterstock
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/markets/equities/24/08/40466130/whats-going-on-with-lucid-group-stock-on-tuesday?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Lucid Group Stock On Tuesday?</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

Markets

SNOW

Snowflake, GeoVax, Zoom, Target, Tesla: Why These 5 Stocks Are On Investors' Radars Today

GeoVax Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares popped ahead of the close on Wednesday and continue to bounce around in extended trading following a report suggesting Michigan&#8217;s Wayne County confirmed its <a href="https://www.benzinga.com/markets/asia/24/08/40446949/mpox-variant-sparks-global-concern-as-europe-china-ramp-up-screening">first case of mpox since 2022</a>.
What Happened: According to a Fox Detroit <a href="https://www.fox2detroit.com/news/mpox-wayne-county-health-department-confirms-first-case-since-2022?taid=66c643be103e400001efc3e9&amp;utm_campaign=trueanthem&amp;utm_medium=trueanthem&amp;utm_source=twitter">report</a>, the Wayne County Health Department announced that a case of mpox was confirmed in a county&nbsp;resident.
The department said it&#8217;s waiting to determine the specific type of the virus and noted that there have been no new cases of the Clade 1 type that&#8217;s behind the <a href="https://www.benzinga.com/markets/asia/24/08/40446949/mpox-variant-sparks-global-concern-as-europe-china-ramp-up-screening">outbreak in Africa</a>.
The World Health Organization (WHO) determined last week that the recent surge of mpox, formerly known as monkeypox, across a growing number of countries in Africa constituted a public health emergency of international concern.
"The emergence of a new clade of mpox, its rapid spread in eastern DRC, and the reporting of cases in several neighbouring countries are very worrying. On top of outbreaks of other mpox clades in DRC and other countries in Africa, it&#8217;s clear that a coordinated international response is needed to stop these outbreaks and save lives," the WHO Director-General&nbsp;recently <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern" target="_blank" rel="noreferrer noopener">said</a>.
Although mpox can be contagious for two to four weeks, it doesn&#8217;t spread through the air. Individuals with mpox will form a rash within a day that resembles blisters on the skin and often have symptoms including fevers, muscle aches and fatigue.
GeoVax&nbsp;is a clinical-stage biotech company focused on developing immunotherapies and vaccines.&nbsp;The company previously published information&nbsp;in&nbsp;peer-reviewed journals suggesting its vaccines help prevent mpox.
See Also: <a href="https://www.benzinga.com/news/24/08/40444353/virax-biolabs-shares-climb-with-mpox-cases-what-to-know">Virax Biolabs Shares Climb With Mpox Cases: What To Know</a>
GOVX Price Action: <a href="http://benzinga.com/quote/govx" target="_blank" rel="noreferrer noopener">GeoVax shares</a> popped ahead of the bell, closing the day up 47%. The stock was down after-hours 0.24% at $8.33 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo:&nbsp;NIAID from Flickr.

GeoVax Labs Stock Surges Ahead Of The Close, Shares Remain Volatile: What's Happening?

WIIM

GeoVax Labs shares are trading higher amid mpox concerns. The stock spiked after the Wayne County Health Department reportedly confirmed the first case since 2022.

GeoVax Labs Shares Halted On Circuit Breaker To The Upside, Stock Now Up 46%

GeoVax Labs (GOVX) has shared an announcement. GeoVax Labs, Inc. has successfully completed a registered direct offering, selling over 1.3 million ...

GeoVax Labs Secures Growth Funding Through Equity Sales

Bavarian Nordic rebounds as new mpox vaccine order boosts outlook

Mpox stocks in focus as Thailand reports first case in Asia linked to new strain

Tonix stock jumps on collaboration for mpox vaccine candidate

Trinity stock soars post-market on raised guidance, increased capacity

GeoVax Labs to raise $5M via private placement

The latest update is out from GeoVax Labs (GOVX). GeoVax Labs, Inc. launched a registered direct offering, selling over 837,000 shares and pre-fund...

GeoVax Labs Accelerates Capital Raise with Multiple Offerings

UNICEF issues emergency tender to secure mpox vaccines

Bavarian Nordic stock slides on Moderna mpox vaccine study

Morocco reports first mpox case amid ongoing global outbreak

APNHF

BVNKF

CODX

RHHBF

RHHBY

TRIB

Press Releases

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

Earnings

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Financing

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now

Registration is Now Open for Tribe Public's Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab's CEO

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

GeoVax to Participate in Upcoming Investor Conferences in September

AAWH

BIDCF

BIXT

BTVRF

CSE:NTAR

CSE:TEX

CVKD

CYIO

ELUT

EUDA

GDTC

GOSS

GOVXW

IMRN

INBS

IQST

LDTC

NEXCF

NMHI

NVAAF

PCYO

PENMF

PGEZF

PRSO

RGBP

SIGY

SUGRF

TRGEF

TSXV:BITK

TSXV:BTV

TSXV:PGE

TSXV:SUG

UMAC

XXII

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Biora Therapeutics

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Cyclo Therapeutics

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

HCW Biologics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lisata Therapeutics

MEI Pharma

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Nanoviricides

Orgenesis

BiomX

Pieris Pharmaceuticals, Inc. - Common Stock

Pieris Pharmaceuticals

RenovoRx

SAB Biotherapeutics

Spruce Biosciences

Surrozen

Unity Biotechnology

Vincerx Pharma

Noble Capital Markets

EF Hutton

HC Wainwright & Co.

Roth MKM

Dawson James

매일의 거래일에는 트레이더들이 전체 시장과 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent080124&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">개별 종목들</a>에 대한 최신 뉴스를 볼 수 있는 소스인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다.
2024년 8월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보자. 현재 가격과 연간 실적은 8월 30일을 기준으로 하며 배당금은 포함되지 않았다. 4월 검색결과는 추적되지 않았다.
1. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
&#8211; 현재가: $119.37 
&#8211; 52주 범위: $39.23 ~ $140.76 
&#8211; 연초 대비 수익률: +147.8% 
&#8211; <a href="https://www.benzinga.com/news/earnings/23/02/30713474/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-january-where-do-spy-tesla-apple-and-ford" target="_blank" rel="noopener" data-google-interstitial="false">1월</a>/<a href="https://www.benzinga.com/markets/penny-stocks/23/03/31137326/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-february-including-tesla-apple-and" target="_blank" rel="noopener" data-google-interstitial="false">2월</a>/<a href="https://www.benzinga.com/markets/equities/24/04/38023764/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-march-where-do-tesla-nvidia-spy-and-re" target="_blank" rel="noopener" data-google-interstitial="false">3월</a> 검색 순위: 3위/1위/1위 
&#8211; <a href="https://www.benzinga.com/exclusives/24/06/39234936/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-may-where-do-nvidia-tesla-gamestop-amc-ran" target="_blank" rel="noopener" data-google-interstitial="false">5월</a>/<a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple" target="_blank" rel="noopener" data-google-interstitial="false">6월</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow" target="_blank" rel="noopener" data-google-interstitial="false">7월</a> 검색 순위: 2위/1위/2위
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
&#8211; 현재가: $563.68 
&#8211; 52주 범위: $409.22 ~ $565.22 
&#8211; 연초 대비 수익률: +19.3% 
&#8211; 1월/2월/3월 검색 순위: 2위/2위/3위 
&#8211; 5월/6월/7월 검색 순위: 1위/3위/3위
3. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
&#8211; 현재가: $214.11 
&#8211; 52주 범위: $138.80 ~ $278.97 
&#8211; 연초 대비 수익률: -13.8% 
&#8211; 1월/2월/3월 검색 순위: 1위/4위/2위 
&#8211; 5월/6월/7월 검색 순위: 4위/4위/1위
4. 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
&#8211; 현재가: $437.70 
&#8211; 52주 범위: $226.59 ~ $1,229.00 
&#8211; 연초 대비 수익률: +53.3% 
&#8211; 1월/2월/3월 검색 순위: 상위 20위 미포함/상위 20위 미포함/5위 
&#8211; 5월/6월/7월 검색 순위: 14위/10위/19위
5. 루멘 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>)
&#8211; 현재가: $5.25 
&#8211; 52주 범위: $0.78 ~ $7.83 
&#8211; 연초 대비 수익률: +17.8% 
&#8211; 1월/2월/3월 검색 순위: 상위 20위 미포함 
&#8211; 5월/6월/7월 검색 순위: 상위 20위 미포함
6. 애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
&#8211; 현재가: $229.00 
&#8211; 52주 범위: $164.08 ~ $237.23 
&#8211; 연초 대비 수익률: +23.4% 
&#8211; 1월/2월/3월 검색 순위: 5위/8위/4위 
&#8211; 5월/6월/7월 검색 순위: 6위/5위/7위
7. 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
&#8211; 현재가: $31.48 
&#8211; 52주 범위: $13.68 ~ $33.12 
&#8211; 연초 대비 수익률: +89.9% 
&#8211; 1월/2월/3월 검색 순위: 상위 20위 미포함/상위 20위 미포함/11위 
&#8211; 5월/6월/7월 검색 순위: 6위/5위/7위
8. 어드밴스드 마이크로 디바이시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
&#8211; 현재가: $148.56 
&#8211; 52주 범위: $93.12 ~ $227.30 
&#8211; 연초 대비 수익률: +7.2% 
&#8211; 1월/2월/3월 검색 순위: 12위/14위/8위 
&#8211; 5월/6월/7월 검색 순위: 8위/9위/4위
9. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
&#8211; 현재가: $476.27 
&#8211; 52주 범위: $342.35 ~ $503.52 
&#8211; 연초 대비 수익률: +18.3% 
&#8211; 1월/2월/3월 검색 순위: 18위/상위 20위 미포함/9위 
&#8211; 5월/6월/7월 검색 순위: 9위/11위/11위
10. 지오백스 랩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>)
&#8211; 현재가: $4.63 
&#8211; 52주 범위: $1.09 ~ $11.18 
&#8211; 연초 대비 수익률: -16.6% 
&#8211; 1월/2월/3월 검색 순위: 상위 20위 미포함 
&#8211; 5월/6월/7월 검색 순위: 상위 20위 미포함
주목할 만한 종목들: 다음 주식들은 2024년 상반기에 Benzinga Pro에서 11위에서 20위까지 가장 많이 검색된 종목들이었다.
11. 인도네시아 에너지 코퍼레이션 (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INDO#AMEX">INDO</a>)
12. 바이랙스 바이오랩스 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>)
13. 아마존닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
14. 싱귤레이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>)
15. 메타 플랫폼스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
16. 서브 로보틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>)
17. 어플라이드 DNA 사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>)
18. AST 스페이스모바일 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)
19. 크라우드스트라이크 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)
20. 인튜이티브 머신스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
중요한 이유 (Why It&#8217;s Important): 엔비디아는 해당 월 동안 <a href="https://www.benzinga.com/news/earnings/24/08/40613050/nvidia-q2-earnings-guidance-top-street-view-as-ai-fuels-record-data-center-revenue-gross-margin-fal" target="_blank" rel="noopener" data-google-interstitial="false">분기별 실적 발표</a>가 있어서 8월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식이었다. 이 회사는 분석가들의 추정치를 웃돌았고, 추정치보다 앞선 지침을 공유했다. 해당 주식은 올해 매달 Benzinga Pro에서 가장 많이 검색된 상위 3개 종목 중 하나로 꾸준히 선정되었다.
7월 1위를 차지했던 테슬라는 8월 3위로 떨어졌다. 이 전기 자동차 주식은 2024년 동안 매달 가장 많이 검색된 4개 종목 중 하나로 선정되었다.
8월에는 두 개의 ETF가 가장 많이 검색된 종목 중 하나였으며 SPY가 2위, QQQ가 9위를 차지했다. S&amp;P 500을 추적하는 SPY는 매월 가장 많이 검색되는 상위 3개 종목 중 하나로 정기적으로 선정되었다. 나스닥 100을 추적하는 QQQ는 8월 상승세를 보이며 5월 이후 처음으로 다시 톱 10에 진입했다.
슈퍼 마이크로 컴퓨터는 8월에 <a href="https://www.benzinga.com/trading-ideas/short-ideas/24/08/40579899/super-micro-computer-stock-falls-on-short-report-hindenburg-says-company-has-accounting" target="_blank" rel="noopener">공매도 보고서</a>와 회사의 업데이트로 인해 관심이 급증한 것으로 보인다. 지난 3월 5위까지 올랐던 주가는 8월 4위를 기록했다. 주가는 6월 10위 이후 처음으로 다시 10위권 안으로 진입했다.
신규 주식 두 종목이 상위 10개 종목 목록에 합류했으며, 루멘 테크놀로지스는 5위, 지오백스 랩스는 10위를 차지했다. 루멘은 이번 달 <a href="https://www.benzinga.com/news/24/08/40221474/lumen-technologies-stock-continues-to-soar-whats-going-on" target="_blank" rel="noopener">분기별 재무 결과를 발표</a>한 후 주가가 급등하고 투자자들의 관심을 받았다. 지오백스 랩스는 엠폭스(mpox, 원숭이두창)에 대한 세계보건기구(WHO)의 <a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal" target="_blank" rel="noopener">긴급 보건 선언</a>과 관련하여 높은 변동성과 관심 증가를 확인했다. 지오백스 랩스에는 엠폭스에 효과적이라고 알려진 백신이 있다.
상위 10위권에는 8월 16위를 차지한 서브 로보틱스와 8월 상위 20위 안에 들지 못한 잽 전기차 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>)이 포함되었다.
iShares Russell 2000 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>)는 독자들의 지속적인 관심을 받고 있다. 소형주를 추적하는 이 ETF는 7월 22위에 이어 8월에는 24위에 올랐다. 잠재적인 연방준비제도의 금리 인하가 임박함에 따라 9월에는 소형주와 ETF에 대한 관심이 높아질 수 있다.
Photo created using artificial intelligence via MidJourney.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지오백스 랩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>)의 주가는 수요일 뉴욕 시장 마감을 앞두고 급등했고, 미시간주 웨인(Wayne) 카운티에서 <a href="https://www.benzinga.com/markets/asia/24/08/40446949/mpox-variant-sparks-global-concern-as-europe-china-ramp-up-screening" target="_blank" rel="noopener" data-google-interstitial="false">2022년 이후 첫 번째 엠폭스</a>(mpox, 원숭이두창) 사례가 확인됐다는 보도가 나온 후 시간외 거래에서 계속해서 반등했다.
무슨 일이 (What Happened): 폭스 디트로이트(Fox Detroit) <a href="https://www.fox2detroit.com/news/mpox-wayne-county-health-department-confirms-first-case-since-2022?taid=66c643be103e400001efc3e9&amp;utm_campaign=trueanthem&amp;utm_medium=trueanthem&amp;utm_source=twitter">보도에 따르면</a>, 웨인 카운티 보건부는 한 카운티 거주자에게서 엠폭스 사례가 확인되었다고 발표했다.
이 보건부는 바이러스의 특정 유형을 결정하기 위해 기다리고 있다고 말했으며 <a href="https://www.benzinga.com/markets/asia/24/08/40446949/mpox-variant-sparks-global-concern-as-europe-china-ramp-up-screening" target="_blank" rel="noopener" data-google-interstitial="false">아프리카에서 발병</a>의 배후에 있는 클레이드(Clade) 1 유형의 새로운 사례는 없다고 언급했다.
세계보건기구(WHO)는 지난주 아프리카의 점점 더 많은 국가들에서 이전에 원숭이두창으로 알려졌던 엠폭스의 급증이 국제적 우려의 공중보건 비상사태에 해당한다고 결정했다.
&#8220;새로운 클레이드의 엠폭스 출현, 동부 콩고민주공화국(DRC)에서의 빠른 확산, 그리고 인접 여러 국가들에서의 사례 보고는 매우 우려스럽다. DRC와 아프리카 다른 국가들에서의 다른 엠폭스 클레이드의 발병에 더해, 이러한 발병을 막고 생명을 구하기 위해서는 국제적인 협조가 필요하다는 것이 분명하다,&#8221;고 WHO 사무총장이 최근에 <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern" target="_blank" rel="noreferrer noopener">말했</a>다.
엠폭스는 2주에서 4주 동안 전염될 수 있지만, 공기를 통해 전파되지는 않는다. 엠폭스에 걸린 사람은 하루 안에 피부에 물집과 유사한 발진이 생기며, 종종 발열, 근육통 및 피로와 같은 증상을 동반한다.
지오백스(GeoVax)는 면역 요법 및 백신 개발에 주력하는 임상 단계의 바이오테크 회사이다. 이 회사는 이전에 동료 기업들의 평가를 받은 저널에 자사 백신이 엠폭스 예방에 도움이 된다는 정보를 발표한 바 있다.
참고: <a href="https://www.benzinga.com/news/24/08/40444353/virax-biolabs-shares-climb-with-mpox-cases-what-to-know">엠폭스 사례 증가로 바이랙스 바이오랩스 주식 상승: 알아야 할 사항</a>
GOVX 주가 움직임: 지오백스의 주식은 시장 마감 전 급등하며 수요일 정규 거래를 47.01% 상승하여 마감했다. 이후 애프터 마켓에서 13.53% 추가 상승하여 9.48달러를 기록했다.
사진: NIAID 출처: Flickr.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Geovax Labs

뉴스

에 대한 최신 뉴스 Geovax Labs (NASDAQ:GOVX) 주식

수요일, 9월 04, 2024

수요일, 8월 21, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌